Certara (NASDAQ:CERT) Updates FY 2025 Earnings Guidance

Certara (NASDAQ:CERT) issued an update on its FY 2025 earnings guidance on Thursday morning. The company provided earnings per share (EPS) guidance of 0.450-0.470 for the period, compared to the consensus estimate of 0.370. The company issued revenue guidance of $415.0 million-$420.0 million, compared to the consensus revenue estimate of $421.7 million.

Certara Price Performance

Shares of Certara stock traded down $2.60 on Friday, hitting $8.67. 9,104,388 shares of the company were exchanged, compared to its average volume of 1,604,633. The company has a quick ratio of 2.16, a current ratio of 2.16 and a debt-to-equity ratio of 0.27. The stock has a market capitalization of $1.39 billion, a price-to-earnings ratio of 123.86 and a beta of 1.44. The company has a 50-day moving average price of $11.77 and a 200 day moving average price of $11.51. Certara has a 1-year low of $8.47 and a 1-year high of $15.69.

Certara (NASDAQ:CERT) last announced its quarterly earnings results on Thursday, November 6th. The company reported $0.14 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.11 by $0.03. The business had revenue of $104.62 million during the quarter, compared to the consensus estimate of $104.53 million. Certara had a net margin of 2.62% and a return on equity of 5.17%. During the same quarter last year, the firm earned $0.13 EPS. Certara has set its FY 2025 guidance at 0.450-0.470 EPS. As a group, sell-side analysts predict that Certara will post 0.28 earnings per share for the current fiscal year.

Analysts Set New Price Targets

CERT has been the topic of a number of recent analyst reports. Zacks Research raised shares of Certara from a “strong sell” rating to a “hold” rating in a research report on Friday, September 5th. KeyCorp raised their price objective on shares of Certara from $15.00 to $16.00 and gave the company an “overweight” rating in a research note on Wednesday, October 8th. Craig Hallum began coverage on shares of Certara in a report on Monday, September 29th. They issued a “buy” rating and a $16.00 price objective for the company. Barclays reduced their target price on shares of Certara from $16.00 to $14.00 and set an “overweight” rating on the stock in a report on Friday. Finally, Weiss Ratings restated a “sell (d)” rating on shares of Certara in a research note on Wednesday, October 8th. Six investment analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $15.38.

Insider Buying and Selling at Certara

In related news, insider Leif E. Pedersen sold 51,224 shares of the stock in a transaction on Tuesday, September 9th. The stock was sold at an average price of $10.92, for a total value of $559,366.08. Following the transaction, the insider owned 73,979 shares of the company’s stock, valued at $807,850.68. This represents a 40.91% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Insiders own 2.33% of the company’s stock.

Institutional Investors Weigh In On Certara

A number of institutional investors and hedge funds have recently bought and sold shares of CERT. Osaic Holdings Inc. increased its holdings in shares of Certara by 50.7% in the second quarter. Osaic Holdings Inc. now owns 3,491 shares of the company’s stock valued at $41,000 after purchasing an additional 1,175 shares during the period. Tower Research Capital LLC TRC grew its position in Certara by 499.5% in the 2nd quarter. Tower Research Capital LLC TRC now owns 5,917 shares of the company’s stock valued at $69,000 after buying an additional 4,930 shares during the last quarter. Canada Pension Plan Investment Board acquired a new position in Certara in the 2nd quarter valued at $83,000. Corient Private Wealth LLC raised its position in Certara by 11.7% during the 2nd quarter. Corient Private Wealth LLC now owns 12,362 shares of the company’s stock worth $144,000 after buying an additional 1,295 shares during the last quarter. Finally, XTX Topco Ltd acquired a new stake in shares of Certara in the 2nd quarter worth $183,000. 73.96% of the stock is owned by hedge funds and other institutional investors.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.